Terje R. Pedersen
Impact in
- Endocrinology, Diabetes and Metabolism top 0.05%
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Surgery top 0.01%
- Lipoproteins and Cardiovascular Health
Papers in
- Surgery 104
- Lipoproteins and Cardiovascular Health 100
-
- Cardiac Valve Diseases and Treatments 25
- Cardiovascular Function and Risk Factors 9
- Co-authors
- Anders Olsson (39 shared papers)John Kjekshus (17 shared papers)Kalevi Pyörälà (10 shared papers)Ole Færgeman (22 shared papers)Ingar Holme (41 shared papers)Robert P. Giugliano (32 shared papers)Marc S. Sabatine (33 shared papers)Anthony Keech (31 shared papers)
- Journals
- Circulation (21 papers)The American Journal of Cardiology (20 papers)Journal of the American College of Cardiology (12 papers)Atherosclerosis (10 papers)JAMA Cardiology (9 papers)
- Partner nations
- NorwayUnited StatesUnited Kingdom
In The Last Decade
Terje R. Pedersen
171 papers receiving 24.4k citations
Terje R. Pedersen's Hit Papers
Peers
Comparison fields: 5 of 145
- Endocrinology, Diabetes and Metabolism 5.4k
- Surgery 13.8k
- Cardiology and Cardiovascular Medicine 5.7k
- Cancer Research 2.2k
- Transplantation 380
Countries citing papers authored by Terje R. Pedersen
This map shows the geographic impact of Terje R. Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terje R. Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terje R. Pedersen more than expected).
Fields of papers citing papers by Terje R. Pedersen
This network shows the impact of papers produced by Terje R. Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terje R. Pedersen. The network helps show where Terje R. Pedersen may publish in the future.
Co-authors
The 25 scholars most cited alongside Terje R. Pedersen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 171 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias Hit paper breakdown → | 2016 | 2148 |
| 2 | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 2004 | 1857 |
| 3 | 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias Hit paper breakdown → | 2016 | 1285 |
| 4 | Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1997 | 1202 |
| 5 | High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE> Hit paper breakdown → | 2005 | 1124 |
| 6 | Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis Hit paper breakdown → | 2008 | 1094 |
| 7 | Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials Hit paper breakdown → | 2015 | 1042 |
| 8 | Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes Hit paper breakdown → | 2004 | 974 |
| 9 | Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Hit paper breakdown → | 2003 | 661 |
| 10 | Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Hit paper breakdown → | 2019 | 615 |
| 11 | Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins Hit paper breakdown → | 2012 | 582 |
| 12 | Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease Hit paper breakdown → | 2017 | 510 |
| 13 | Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial Hit paper breakdown → | 2017 | 481 |
| 14 | Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1998 | 478 |
| 15 | 2004 | 421 | |
| 16 | Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial Hit paper breakdown → | 2017 | 413 |
| 17 | Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials Hit paper breakdown → | 2018 | 386 |
| 18 | Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment Hit paper breakdown → | 2008 | 380 |
| 19 | Cognitive Function in a Randomized Trial of Evolocumab Hit paper breakdown → | 2017 | 339 |
| 20 | 1998 | 331 |
About Terje R. Pedersen
Terje R. Pedersen is a scholar working on Surgery, Cardiology and Cardiovascular Medicine, Economics and Econometrics, Endocrinology, Diabetes and Metabolism and Radiology, Nuclear Medicine and Imaging, having authored 171 papers that have together received 25.5k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (100 papers), Cardiac Valve Diseases and Treatments (25 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers), Pharmaceutical Economics and Policy (11 papers), Cardiac Imaging and Diagnostics (11 papers), Cardiovascular Function and Risk Factors (9 papers) and Cancer, Lipids, and Metabolism (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (5.4k citations), Surgery (13.8k citations), Cardiology and Cardiovascular Medicine (5.7k citations), Cancer Research (2.2k citations) and Transplantation (380 citations). Terje R. Pedersen has collaborated with scholars based in Norway, United States and United Kingdom. Frequent co-authors include Anders Olsson, John Kjekshus, Kalevi Pyörälà, Ole Færgeman, Ingar Holme, Robert P. Giugliano, Marc S. Sabatine, Anthony Keech, Guðmundur Þorgeirsson and Alberico L. Catapano. Their work appears in journals such as Circulation, The American Journal of Cardiology, Journal of the American College of Cardiology, Atherosclerosis and JAMA Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.